Health Canada clears Mounjaro to cut cardiovascular risk in type 2 diabetes

Tirzepatide earns a new Canadian indication for adults with established heart disease

Health Canada clears Mounjaro to cut cardiovascular risk in type 2 diabetes

Mounjaro (tirzepatide) carries a new Canadian indication to lower the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with type 2 diabetes and established cardiovascular disease. 

Health Canada issued the Notice of Compliance (NOC), according to an announcement from Eli Lilly Canada. 

The approval rests on SURPASS-CVOT, described by the company as the first cardiovascular outcomes trial comparing two incretin medicines head-to-head rather than against a placebo. 

Per the same announcement, the trial is the largest and longest tirzepatide study to date, enrolling more than 13,000 participants across 30 countries, including Canada, over more than four and a half years. 

In the trial, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit, with an 8 percent lower rate of cardiovascular death, heart attack or stroke (MACE-3).  

Eli Lilly Canada put the estimated hazard ratio for time to first MACE-3 at 0.92, with a 95.3 percent confidence interval of 0.83 to 1.01. 

Harpreet Bajaj, chair of endocrinology research at LMC/Centricity Canada and Canadian national lead trial investigator of SURPASS-CVOT, said “treatment decisions in type 2 diabetes need to reflect the individual needs, health risks and preferences of each patient.”  

Bajaj said the evidence behind the new tirzepatide indication adds an option that manages type 2 diabetes while cutting the risk of serious cardiovascular events in patients at increased risk. 

Jeffrey Habert, assistant professor in the department of family and community medicine at the University of Toronto, said, “managing type 2 diabetes today means looking beyond A1C. We need to address the full cardiometabolic picture, particularly excess weight and cardiovascular risk, both of which have a major impact on our patients’ long-term outcomes.” 

Mathilde Merlet, general manager and president of Lilly Canada, said the new indication “builds on its established benefits, including greater reductions in A1C and weight compared with semaglutide 1 mg, and reflects Lilly’s continued commitment to improving care for people living with type 2 diabetes.” 

Mounjaro is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes. 

Lilly describes it as the first and only Health Canada-approved GIP and GLP-1 receptor agonist in type 2 diabetes, a single molecule that activates the body’s receptors for both hormones. 

Safety and tolerability were generally consistent with the drug’s established profile, Eli Lilly Canada reported.  

The most commonly reported adverse events in SURPASS-CVOT for Mounjaro were gastrointestinal-related, generally mild-to-moderate in severity, and occurred primarily during the dose-escalation period.